Gammapatías monoclonales de significado renal
Reads0
Chats0
TLDR
La importancia de discriminar el termino GMSR radica en poder indicar procedimientos diagnosticos y terapeuticos dirigidos al control of the sintesis y secrecion of las proteinas monoclonales independientemente of los criterios clasicos vinculados with the expansion tumoral maligna.Abstract:
The term monoclonal gammopathy of renal significance (MGRS) comprises a group of diseases pathogenetically characterised by proliferation of a B-cell or plasma cell clone that synthesises and secretes a monoclonal immunoglobulin or its components (light and/or heavy chains), that may deposit and cause glomerular, tubular, interstitial and/or vascular damage. The importance of differentiating the term MGRS from other monoclonal gammopathies lies in the fact that diagnostic and therapeutic procedures aimed at controlling monoclonal protein synthesis and secretion can be indicated, irrespective of the classic criteria based on malignant tumour expansion. Renal pathology associated with MGRS is highly heterogeneous, and therefore renal biopsy should be considered a key diagnostic tool. A precise diagnostic approach, however, must also identify the monoclonal protein in plasma and/or in urine, together with a complete haematological study in order to determine the nature and extension of cell clones. Recent advances in the understanding of these entities have resulted in significant improvements in clinical course and survival in several forms of MGRS, although more studies and clinical experience are needed in order to delineate more effective therapeutic strategies. In this review, we summarise the main clinical and pathological features of MGRS, highlighting the most appropriate diagnostic approach and current therapeutic options.read more
Citations
More filters
Journal ArticleDOI
Update on C3 Glomerulopathy: A Complement-Mediated Disease.
TL;DR: In recent years, several important advances have taken place in the understanding of C3G, but still further studies are warranted to elucidate the best therapeutic strategies that could improve prognosis of this entity.
Journal ArticleDOI
Chronological change of renal pathological findings in the proliferative glomerulonephritis with monoclonal IgG deposits considered to have recurred early after kidney transplantation.
Takayuki Katsuno,Masashi Kato,Takashi Fujita,Naotake Tsuboi,Ryohei Hattori,Yasuhiko Ito,Shoichi Maruyama +6 more
TL;DR: The case of a 46-year-old man who presented with nephrotic syndrome and progressive kidney injury following kidney transplantation and was diagnosed with recurrent PGNMID case in the allograft, where the graft function was eventually lost.
Journal ArticleDOI
Моноклональная гаммапатия ренального значения: консенсус гематологов и нефрологов России по введению нозологии, диагностике и обоснованности клон-ориентированной терапии
А. В. Смирнов,Б. В. Афанасьев,И. В. Поддубная,В. А. Добронравов,М. С. Храброва,Е. В. Захарова,Е А Никитин,Л. В. Козловская,И. Н. Бобкова,В. В. Рамеев,М. М. Батюшин,И С Моисеев,Е И Дарская,О. В. Пирогова,Л. П. Менделеева,Л. С. Бирюкова +15 more
TL;DR: The present Consensus is intended to define the principal practical steps to resolve the problem of MGRS in Russian Federation including the incoherence in nosology classification, diagnostics approach and rationale for clone specific treatment.
Journal ArticleDOI
Monoclonal gammopathy of renal signifi cance: Consensus of hematologists and nephrologists of Russia on the establishment of nosology, diagnostic approach and rationale for clone specific treatment
A. V. Smirnov,Boris V. Afanasyev,I. V. Poddubnaya,V. A. Dobronravov,Maria Khrabrova,Elena Zakharova,E. A. Nikitin,L V Kozlovskaya,Irina Bobkova,V V Rameev,Mikhail M. Batyushin,Ivan S. Moiseev,Elena I. Darskaya,OV Pirogova,L. P. Mendeleeva,L S Biryukova +15 more
TL;DR: The present Consensus is intended to define the principal practical steps to resolve the problem of MGRS in Russian Federation including the incoherence in nosology classification, diagnostics approach and rationale for clone specific treatment.
Journal ArticleDOI
[Monoclonal gammopathy of renal significance: consensus of hematologists and nephrologists of Russia on the establishment of nosology, diagnostic approach and rationale for clone specific treatment].
Alexei Smirnov,Boris V. Afanasyev,I. V. Poddubnaya,Vladimir Dobronravov,Maria Khrabrova,Elena Zakharova,E. A. Nikitin,L V Kozlovskaya,Irina Bobkova,V V Rameev,Mikhail M. Batyushin,Ivan S. Moiseev,Elena I. Darskaya,OV Pirogova,L. P. Mendeleeva,L S Biryukova +15 more
TL;DR: In this article, the authors defined MGRS as kidney injury due to nephrotoxic monoclonal immunoglobulin produced by the B-cell line clone which does not reach the hematological criteria for specific treatment initiation.
References
More filters
Journal ArticleDOI
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
Robert A. Kyle,J. Anthony Child,Kenneth C. Anderson,Bart Barlogie,Régis Bataille,William I. Bensinger,Joan Bladé,Mario Boccadoro,William S. Dalton,Meletios A. Dimopoulos,Benjamin Djulbegovic,Mark T. Drayson,Brian G.M. Durie,Thiery Facon,Rafael Fonseca,Gösta Gahrton,Philip R. Greipp,Jean Luc Harousseau,David P. Harrington,Mohamad A. Hussein,Douglas E. Joshua,Heinz Ludwig,Gareth J. Morgan,Martin M. Oken,R. L. Powles,Paul G. Richardson,David Roodman,Jesús F. San Miguel,Kazuyuki Shimizu,Chaim Shustik,Bhawna Sirohi,Pieter Sonneveld,Guido J Tricot,Ingemar Turesson,Brian G Van Ness,David H. Vesole,Donna M. Weber,Jan Westin,Keith Wheatley +38 more
TL;DR: The International Myeloma Working Group has reviewed the criteria for diagnosis and classification with the aim of producing simple, easily used definitions based on routinely available investigations to facilitate comparison of therapeutic trial data.
Journal ArticleDOI
Prevalence of Monoclonal Gammopathy of Undetermined Significance
Robert A. Kyle,Terry M. Therneau,S. Vincent Rajkumar,Dirk R. Larson,Matthew F. Plevak,Janice R. Offord,Angela Dispenzieri,Jerry A. Katzmann,L. Joseph Melton +8 more
TL;DR: Among residents of Olmsted County, Minnesota, MGUS was found in 3.2% of persons 50 years of age or older and 5.3 percent of persons 70 years ofAge or older, which are higher in men than in women.
Journal ArticleDOI
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos,Albert Oriol,Hareth Nahi,Jesús F. San-Miguel,Nizar J. Bahlis,Saad Z. Usmani,Neil Rabin,Robert Z. Orlowski,Mieczysław Komarnicki,Kenshi Suzuki,Torben Plesner,Sung-Soo Yoon,Dina Ben Yehuda,Paul G. Richardson,Hartmut Goldschmidt,Hartmut Goldschmidt,Donna E. Reece,Steen Lisby,Nushmia Z. Khokhar,Lisa O'Rourke,Christopher Chiu,Xiang Qin,Mary E. Guckert,Tahamtan Ahmadi,Philippe Moreau +24 more
TL;DR: The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma.
Journal ArticleDOI
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Philippe Moreau,Halyna Pylypenko,Sebastian Grosicki,Ievgenii Karamanesht,Xavier Leleu,Maria Grishunina,Grigoriy B Rekhtman,Zvenyslava Masliak,Tadeusz Robak,Anna V Shubina,Bertrand Arnulf,Martin Kropff,James Cavet,Dixie-Lee Esseltine,Huaibao Feng,Suzette Girgis,Helgi van de Velde,William Deraedt,Jean-Luc Harousseau +18 more
TL;DR: The primary objective was to show non-inferiority of subcutaneous versus intravenous bortezomib in terms of overall response rate (ORR) after four cycles in patients with a diagnosis of measurable, secretory multiple myeloma who received one or more dose of drug.
Journal ArticleDOI
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
Giovanni Palladini,Angela Dispenzieri,Morie A. Gertz,Shaji Kumar,Ashutosh D. Wechalekar,Philip N. Hawkins,Stefan Schönland,Ute Hegenbart,Raymond L. Comenzo,Efstathios Kastritis,Meletios A. Dimopoulos,Arnaud Jaccard,Catherine Klersy,Giampaolo Merlini +13 more
TL;DR: This study identifies and validates new criteria for response to first-line treatment in AL amyloidosis, based on their association with survival in large patient populations, and offers surrogate end points for clinical trials.
Related Papers (5)
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.
Nelson Leung,Frank Bridoux,Vecihi Batuman,Aristeidis Chaidos,Paul Cockwell,Vivette D. D'Agati,Angela Dispenzieri,Fernando C. Fervenza,Jean Paul Fermand,Simon D. J. Gibbs,Julian D. Gillmore,Guillermo A. Herrera,Arnaud Jaccard,Dragan Jevremovic,Efstathios Kastritis,Vishal Kukreti,Robert A. Kyle,Helen J. Lachmann,Christopher P. Larsen,Heinz Ludwig,Glen S. Markowitz,Giampaolo Merlini,Peter Mollee,Maria M. Picken,Vincent Rajkumar,Virginie Royal,Paul W. Sanders,Sanjeev Sethi,Christopher P. Venner,Peter M. Voorhees,Ashutosh D. Wechalekar,Brendan M. Weiss,Samih H. Nasr +32 more